{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:27:30Z","timestamp":1793730450217,"version":"4.6.1"},"reference-count":88,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Guizhou Science and Technology Partnership Initiative"},{"name":"Science and Technology Project of Guizhou"},{"name":"Graduate Education Teaching Reform Project of Zunyi Medical University","award":["YJSJG2025029"],"award-info":[{"award-number":["YJSJG2025029"]}],"id":[{"id":"https:\/\/ror.org\/00g5b0g93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Graduate Education Teaching Reform Project of Zunyi Medical University","award":["YJSKYJJ2025028"],"award-info":[{"award-number":["YJSKYJJ2025028"]}],"id":[{"id":"https:\/\/ror.org\/00g5b0g93","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although immune-targeted therapies, particularly agents targeting the interleukin (IL)-23\/IL-17 axis, have markedly improved short-term disease control in psoriasis, inadequate responses in a subset of patients and relapse after treatment discontinuation remain unresolved challenges. One possible reason is that immune-centred therapies may not fully address the active contribution of epidermal keratinocytes to inflammatory amplification and disease persistence. In this review, we integrate immune-driven inflammation and epidermal amplification mechanisms from a loop- and network-based perspective, and \u00adpropose an immune\u2013epidermal dual-targeting framework centred on proinflammatory feedback between immune cells and keratinocytes. We systematically summarize three potential implementation routes: combination therapy, single-agent dual targeting and blockade of bridging nodes within immune\u2013epidermal feedback circuits. We further discuss the potential roles and realistic boundaries of artificial intelligence and multi-omics analysis, organoids and engineered skin models, and precision local delivery technologies in target discovery, mechanistic validation and therapeutic translation. Importantly, this framework is not intended to replace existing therapeutic paradigms, but rather to refine their mechanistic interpretation and extend future therapeutic strategies. It may provide additional translational opportunities for stratified, stage-specific and precision management of psoriasis, although several components remain at the stage of mechanistic research and clinical validation.<\/jats:p>","DOI":"10.1093\/bjd\/ljag390","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:20:19Z","timestamp":1788780019000},"source":"Crossref","is-referenced-by-count":0,"title":["Immune\u2013epidermal dual targeting in psoriasis: emerging technologies and translational therapeutic strategies"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3999-1785","authenticated-orcid":false,"given":"Meijun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinzhi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5199-8843","authenticated-orcid":false,"given":"Cong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Xu","sequence":"additional","affiliation":[{"name":"Biology and Medicine Program, School of Bioengineering, Zhuhai Campus, Zunyi Medical University , Zhuhai, Guangdong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The First Affiliated Hospital of Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-3988","authenticated-orcid":false,"given":"Ming","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine & Key Laboratory of Cancer Prevention and Treatment of Guizhou Province, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Special Key Laboratory of Gene Detection & Therapy, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]},{"name":"Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University , Zunyi, Guizhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026110312413230000_ljag390-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2026110312413230000_ljag390-B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026110312413230000_ljag390-B3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis \u2013 current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026110312413230000_ljag390-B4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjd.16809","article-title":"Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM)","volume":"180","author":"Sbidian","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaad.2025.01.055","article-title":"Early inadequate response to biological agents portends treatment failure at 6\u2005months in patients with psoriasis: a multicenter, prospective cohort study","volume":"92","author":"Jiang","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026110312413230000_ljag390-B6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"2026110312413230000_ljag390-B7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026110312413230000_ljag390-B8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1286344","article-title":"Crosstalk: keratinocytes and immune cells in psoriasis","volume":"14","author":"Kamata","year":"2023","journal-title":"Front Immunol"},{"key":"2026110312413230000_ljag390-B9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"key":"2026110312413230000_ljag390-B10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102916","article-title":"Pathogenesis, multi-omics research, and clinical treatment of psoriasis","volume":"133","author":"Yu","year":"2022","journal-title":"J Autoimmun"},{"key":"2026110312413230000_ljag390-B11","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3389\/fimmu.2018.01549","article-title":"The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front Immunol"},{"key":"2026110312413230000_ljag390-B12","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.3390\/ijms21186604","article-title":"Role of innate immune cells in psoriasis","volume":"21","author":"Sato","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026110312413230000_ljag390-B13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026110312413230000_ljag390-B14","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2026110312413230000_ljag390-B15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41419-020-2495-z","article-title":"Keratinocyte transglutaminase 2 promotes CCR6+ \u03b3\u03b4T-cell recruitment by upregulating CCL20 in psoriatic inflammation","volume":"11","author":"Shin","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026110312413230000_ljag390-B16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cytogfr.2020.06.006","article-title":"IL-36 in chronic inflammation and cancer","volume":"55","author":"Neurath","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026110312413230000_ljag390-B17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/ijms21020625","article-title":"Immunological memory of psoriatic lesions","volume":"21","author":"Owczarczyk Saczonek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026110312413230000_ljag390-B18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bjd.12812","article-title":"Interferon-\u03b3\/CCR5 expression in invariant natural killer T cells and CCL5 expression in capillary veins of dermal papillae correlate with development of psoriasis vulgaris","volume":"170","author":"Kono","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B19","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.3390\/ijms22169004","article-title":"Tissue-resident memory T cells in skin diseases: a systematic review","volume":"22","author":"Emmanuel","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026110312413230000_ljag390-B20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: from remission to recurrence","volume":"154","author":"Francis","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026110312413230000_ljag390-B21","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.3390\/ijms24054556","article-title":"Psoriatic resolved skin epidermal keratinocytes retain disease-residual transcriptomic and epigenomic profiles","volume":"24","author":"Ghaffarinia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026110312413230000_ljag390-B22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026110312413230000_ljag390-B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100116","article-title":"The relapse of psoriasis: mechanisms and mysteries","volume":"2","author":"Tian","year":"2022","journal-title":"JID Innov"},{"key":"2026110312413230000_ljag390-B24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41419-019-2212-y","article-title":"Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation","volume":"11","author":"Thatikonda","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026110312413230000_ljag390-B25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41419-021-04230-5","article-title":"MiR-193b-3p\u2013ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes","volume":"12","author":"Huang","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026110312413230000_ljag390-B26","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jid.2017.05.012","article-title":"miR-146b probably assists miRNA-146a in the suppression of keratinocyte proliferation and inflammatory responses in psoriasis","volume":"137","author":"Hermann","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2026110312413230000_ljag390-B27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/bjd.21232","article-title":"miR-378a regulates keratinocyte responsiveness to interleukin-17A in psoriasis","volume":"187","author":"Xia","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B28","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202215674","article-title":"Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis","volume":"15","author":"Wang","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026110312413230000_ljag390-B29","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/jid.2014.89","article-title":"MiR-146a negatively regulates TLR2-induced inflammatory responses in keratinocytes","volume":"134","author":"Meisgen","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2026110312413230000_ljag390-B30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jamadermatol.2014.3456","article-title":"Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the medical board of the National Psoriasis Foundation","volume":"151","author":"Armstrong","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026110312413230000_ljag390-B31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40257-014-0089-1","article-title":"Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say?","volume":"15","author":"Jensen","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"2026110312413230000_ljag390-B32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/14740338.2020.1722640","article-title":"Safety considerations with combination therapies for psoriasis","volume":"19","author":"Nakamura","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2026110312413230000_ljag390-B33","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.3390\/ijms25094681","article-title":"Inhibition of the JAK-STAT pathway in the treatment of psoriasis: a review of the literature","volume":"25","author":"Furtunescu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026110312413230000_ljag390-B34","first-page":"2286","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study","volume":"41","author":"Mease","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026110312413230000_ljag390-B35","first-page":"153","article-title":"Tacrolimus for the management of psoriasis: clinical utility and place in therapy","volume":"6","author":"Malecic","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"2026110312413230000_ljag390-B36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026110312413230000_ljag390-B37","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"2026110312413230000_ljag390-B38","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026110312413230000_ljag390-B39","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00018-020-03726-1","article-title":"Immune responses and therapeutic options in psoriasis","volume":"78","author":"Afonina","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"2026110312413230000_ljag390-B40","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41467-025-67917-9","article-title":"Dynamic neutrophil\u2013keratinocyte communication network centered on IL-36\/TNFSF15 responses characterizes inflammatory responses in generalized pustular psoriasis","volume":"17","author":"Jiang","year":"2025","journal-title":"Nat Commun"},{"key":"2026110312413230000_ljag390-B41","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"2026110312413230000_ljag390-B42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaci.2025.03.019","article-title":"TNF-\u03b1 counters skin inflammation by restraining mast cell-dependent thymic stromal lymphopoietin production","volume":"156","author":"Redhu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026110312413230000_ljag390-B43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaci.2014.04.022","article-title":"Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis","volume":"134","author":"Volpe","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2026110312413230000_ljag390-B44","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103865","article-title":"Combination targeted therapy with two biologic\/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy","volume":"24","author":"Lignou","year":"2025","journal-title":"Autoimmun Rev"},{"key":"2026110312413230000_ljag390-B45","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of systemic treatment response in people with psoriasis: a scoping review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B46","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"2026110312413230000_ljag390-B47","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/bjd.18741","article-title":"Predicting the long-term outcomes of biologics in patients with psoriasis using machine learning","volume":"182","author":"Emam","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jid.2018.04.041","article-title":"A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis","volume":"139","author":"Foulkes","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2026110312413230000_ljag390-B49","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq7991","article-title":"Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems","volume":"8","author":"Castillo","year":"2023","journal-title":"Sci Immunol"},{"key":"2026110312413230000_ljag390-B50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jid.2024.07.006","article-title":"How can spatial transcriptomic profiling advance our understanding of skin diseases?","volume":"145","author":"Kumaran","year":"2025","journal-title":"J Invest Dermatol"},{"key":"2026110312413230000_ljag390-B51","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41467-024-44994-w","article-title":"Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockade","volume":"15","author":"Francis","year":"2024","journal-title":"Nat Commun"},{"key":"2026110312413230000_ljag390-B52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s43856-025-01325-4","article-title":"Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity","volume":"6","author":"Rider","year":"2026","journal-title":"Commun Med"},{"key":"2026110312413230000_ljag390-B53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105222","article-title":"Exploratory multi-omics analysis reveals host-microbe interactions associated with disease severity in psoriatic skin","volume":"105","author":"Yang","year":"2024","journal-title":"EBioMedicine"},{"key":"2026110312413230000_ljag390-B54","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jid.2021.06.019","article-title":"Mouse models of psoriasis: a comprehensive review","volume":"142","author":"Gangwar","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2026110312413230000_ljag390-B55","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.803218","article-title":"In vitro disease models for understanding psoriasis and atopic dermatitis","volume":"10","author":"Sarama","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2026110312413230000_ljag390-B56","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.jid.2024.04.032","article-title":"Targeting the complexity of in vitro skin models: a review of cutting-edge developments","volume":"144","author":"Qu\u00edlez","year":"2024","journal-title":"J\u00a0Invest Dermatol"},{"key":"2026110312413230000_ljag390-B57","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2024.01.031","article-title":"Advances in skin-on-a-chip technologies for dermatological disease modeling","volume":"144","author":"Cho","year":"2024","journal-title":"J Invest Dermatol"},{"key":"2026110312413230000_ljag390-B58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-020-2352-3","article-title":"Hair-bearing human skin generated entirely from pluripotent stem cells","volume":"582","author":"Lee","year":"2020","journal-title":"Nature"},{"key":"2026110312413230000_ljag390-B59","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jid.2023.07.017","article-title":"Applications of human pluripotent stem cell-derived skin organoids in dermatology","volume":"143","author":"Sandoval","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"2026110312413230000_ljag390-B60","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3390\/cells11182904","article-title":"Gene profiling of a 3D Psoriatic skin model enriched in T cells: downregulation of PTPRM promotes keratinocyte proliferation through excessive ERK1\/2 signaling","volume":"11","author":"Rioux","year":"2022","journal-title":"Cells"},{"key":"2026110312413230000_ljag390-B61","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2014.1111","article-title":"Combined use of systemic agents for psoriasis: a systematic review","volume":"150","author":"Busard","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2026110312413230000_ljag390-B62","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.7150\/thno.69999","article-title":"Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment","volume":"12","author":"Qu","year":"2022","journal-title":"Theranostics"},{"key":"2026110312413230000_ljag390-B63","doi-asserted-by":"crossref","first-page":"12307","DOI":"10.2147\/IJN.S529899","article-title":"Advances in the drug delivery systems for psoriasis topical therapy","volume":"20","author":"Liu","year":"2025","journal-title":"Int J Nanomed"},{"key":"2026110312413230000_ljag390-B64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113581","article-title":"Dendritic lipopeptide-based transdermal siRNA delivery systems for effective non-invasive therapy in psoriasis","volume":"381","author":"Ma","year":"2025","journal-title":"J Control Release"},{"key":"2026110312413230000_ljag390-B65","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2888","article-title":"Microneedle-assisted genome editing: a transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders","volume":"7","author":"Wan","year":"2021","journal-title":"Sci Adv"},{"key":"2026110312413230000_ljag390-B66","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acsnano.2c08979","article-title":"Reactive oxygen species-responsive gel-based microneedle patches for prolonged and intelligent psoriasis management","volume":"17","author":"Bi","year":"2023","journal-title":"ACS Nano"},{"key":"2026110312413230000_ljag390-B67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125385","article-title":"A new era of psoriasis treatment: drug repurposing through the lens of nanotechnology and machine learning","volume":"673","author":"Tarek","year":"2025","journal-title":"Int J Pharm"},{"key":"2026110312413230000_ljag390-B68","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1039\/D3TB02643D","article-title":"Microneedle-assisted percutaneous delivery of methotrexate-loaded nanoparticles enabling sustained anti-inflammatory effects in psoriasis therapy","volume":"12","author":"Du","year":"2024","journal-title":"J Mater Chem B"},{"key":"2026110312413230000_ljag390-B69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113794","article-title":"Dissolving microneedles in transdermal drug delivery: a critical analysis of limitations and translation challenges","volume":"383","author":"Moawad","year":"2025","journal-title":"J Control Release"},{"key":"2026110312413230000_ljag390-B70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.actbio.2025.10.008","article-title":"Advancing dermatology with skin equivalents and organoids in pathophysiology and drug testing","volume":"207","author":"Lakeh","year":"2025","journal-title":"Acta Biomater"},{"key":"2026110312413230000_ljag390-B71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41378-025-01149-1","article-title":"Innovations in skin microphysiological systems for nonclinical testing and FDA modernization","volume":"12","author":"Lee","year":"2026","journal-title":"Microsyst Nanoeng"},{"key":"2026110312413230000_ljag390-B72","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2026110312413230000_ljag390-B73","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B74","doi-asserted-by":"crossref","first-page":"e1042","DOI":"10.1111\/jdv.20839","article-title":"Efficacy and safety of dual biologic therapy in inflammatory skin diseases: a systematic review","volume":"39","author":"McMullen","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026110312413230000_ljag390-B75","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/jvc2.525","article-title":"Development and evaluation of an online training tool to aid in the diagnosis of chronic plaque psoriasis","volume":"4","author":"Abo-Tabik","year":"2025","journal-title":"JEADV Clin Pract"},{"key":"2026110312413230000_ljag390-B76","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40257-021-00623-6","article-title":"Steroid Phobia: a review of prevalence, risk factors, and interventions","volume":"22","author":"Contento","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2026110312413230000_ljag390-B77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189765","article-title":"Biologicals and small molecules in psoriasis: a systematic review of economic evaluations","volume":"13","author":"Kromer","year":"2018","journal-title":"PLOS ONE"},{"key":"2026110312413230000_ljag390-B78","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","article-title":"Clinical goals and barriers to effective psoriasis care","volume":"9","author":"Strober","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026110312413230000_ljag390-B79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjd.12039","article-title":"Adherence to medication in patients with psoriasis: a systematic literature review","volume":"168","author":"Thorneloe","year":"2013","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2020.04.095","article-title":"Role of phototherapy in the era of biologics","volume":"84","author":"Torres","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026110312413230000_ljag390-B81","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ijd.17236","article-title":"Disparities and barriers to the access of biologics in moderate-to-severe adult psoriasis","volume":"63","author":"Wan","year":"2024","journal-title":"Int J Dermatol"},{"key":"2026110312413230000_ljag390-B82","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMp1101548","article-title":"Development of novel combination therapies","volume":"364","author":"Woodcock","year":"2011","journal-title":"N Engl J Med"},{"key":"2026110312413230000_ljag390-B83","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cimb46040186","article-title":"Precision dermatology: a review of molecular biomarkers and personalized therapies","volume":"46","author":"Tan","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"2026110312413230000_ljag390-B84","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13643-020-01395-6","article-title":"Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups","volume":"9","author":"Wade","year":"2020","journal-title":"Syst Rev"},{"key":"2026110312413230000_ljag390-B85","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/bjd\/ljaf403","article-title":"Breaking the cycle of psoriasis: the role for early intervention","volume":"194","author":"Graier","year":"2026","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B86","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026110312413230000_ljag390-B87","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.18846","article-title":"Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study","volume":"37","author":"Iversen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026110312413230000_ljag390-B88","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/1346-8138.17471","article-title":"Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis","volume":"51","author":"Choon","year":"2024","journal-title":"J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag390\/70989469\/ljag390.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag390\/70989469\/ljag390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:41:52Z","timestamp":1793727712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag390\/8787785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":88,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag390","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"ljag390"}}